Nov 11, 2021 Proactive Investors: Vyant Bio Reports Total Revenue of $1.5M in 3Q 2021, Shares Strategic Updates
Oct 19, 2021 Proactive Investors: Vyant Bio Forges Partnership with MASORI Therapeutics to Pursue Co-Development Partnerships with Pharma Companies
Oct 11, 2021 Proactive Investors: HC Wainwright Initiates Coverage on Vyant Bio with 'Buy' Recommendation and $5 Price Target
